Loading...
Bevacizumab in ovarian cancer: A critical review of phase III studies
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line tre...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355353/ https://ncbi.nlm.nih.gov/pubmed/27852039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13310 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|